Soraya Soledad Bosch

Soraya Soledad Bosch
Toscana Life Sciences · MAD LAB

Biotechnologist

About

8
Publications
4,167
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
100
Citations
Introduction
Soraya S. Bosch started a Bachelor and Master’s degree in Biotechnology in March of 2006, at the University of Rosario (UNR) in Argentina. In April 2021, she continues her career as a Post-Doctoral researcher joining the "Monoclonal Antibody Discovery Laboratory" (MAD-Lab) team led by Dr. Rino Rappuoli at Fondazione Toscana Life Sciences (TLS), in Siena.
Additional affiliations
August 2013 - present
University of São Paulo
Position
  • PhD Student
August 2013 - present
University of Groningen
Position
  • PhD Student
Description
  • I´m enrolled in a double degree diploma between the University of São Paulo and the University of Groningen.
Education
February 2006 - September 2012
Rosario National University
Field of study
  • Biotechnology

Publications

Publications (8)
Preprint
Full-text available
The silent pandemic caused by antimicrobial resistance (AMR) requires innovative therapeutic approaches. Human monoclonal antibodies (mAbs), which are among the most transformative, safe and effective drugs in oncology and autoimmunity, are rarely used for infectious diseases and not yet used for AMR. Here we applied an antigen-agnostic strategy to...
Article
Full-text available
Malaria is a tropical disease that kills about half a million people around the world annually. Enzymatic reactions within the pyrimidine biosynthesis have been proven to be essential for Plasmodium proliferation. Here we report on the essentiality of the second enzymatic step of the pyrimidine biosynthesis pathway, catalysed by Aspartate Transcarb...
Article
Full-text available
Introduction: Malaria is one of the most prevalent human infections worldwide with over 40% of the world’s population living in malaria-endemic areas. In the absence of an effective vaccine, emergence of drug-resistant strains requires urgent drug development. Current methods applied to drug target validation, a crucial step in drug discovery, poss...
Article
Full-text available
The appearance of multi‐drug resistant strains of malaria poses a major challenge to human health and validated drug targets are urgently required. To define a protein's function in vivo and thereby validate it as a drug target, highly specific tools are required that modify protein function with minimal cross‐reactivity. While modern genetic appro...
Article
Full-text available
Aspartate transcarbamoylase catalyses the second step of de-novo pyrimidine biosynthesis. As malarial parasites lack pyrimidine salvage machinery and rely on de-novo production for growth and proliferation, this pathway is a target for drug discovery. Previously, an apo crystal structure of aspartate transcarbamoylase from Plasmodium falciparum (Pf...
Article
Full-text available
The de novo pyrimidine-biosynthesis pathway of Plasmodium falciparum is a promising target for antimalarial drug discovery. The parasite requires a supply of purines and pyrimidines for growth and proliferation and is unable to take up pyrimidines from the host. Direct (or indirect) inhibition of de novo pyrimidine biosynthesis via dihydroorotate d...
Article
Full-text available
Apicomplexan parasites cause infectious diseases that are either a severe public health problem or an economic burden. In this paper we will shed light on how oxidative stress can influence the host-pathogen relationship by focusing on three major diseases: babesiosis, coccidiosis, and toxoplasmosis.

Questions

Question (1)
Question
I need the pTEX sequence or the complete pTEX-GFP. I don't have the license of the molecular programs so I'm currently doing it by hand with the trial versions but it's taking my a lot of time. If anybody could help me I will appreciate a lot!

Network

Cited By